Clinical data | |
---|---|
Trade names | Monoferric, Monofer |
Other names | FDI |
AHFS/Drugs.com | Monograph |
License data | |
Routes of administration | Intravenous |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C18H34FeO16+3 |
Molar mass | 562.299 g·mol−1 |
3D model (JSmol) | |
| |
|
Ferric derisomaltose, sold under the brand name Monoferric among others, is a medication for the treatment of iron deficiency anemia in adults who have intolerance to oral iron or have had unsatisfactory response to oral iron or who have non-hemodialysis dependent chronic kidney disease (NDD-CKD). [4] It was approved for use in the United States in January 2020. [4] [5] [6] It is given intravenously. [4]